Division of Stomach surgery, Department of Surgery, Asan Medical Center, College of Medicine, University of Ulsan, Seoul, Korea.
BMC Complement Altern Med. 2012 Oct 3;12:172. doi: 10.1186/1472-6882-12-172.
Mistletoe (Viscum album L.) extracts are widely used in complementary cancer therapy. Aim of this study was to evaluate safety and efficacy of a standardized mistletoe extract (abnobaVISCUM(®) Quercus, aVQ) in patients with gastric cancer.
32 operated gastric cancer patients (stage Ib or II) who were waiting for oral chemotherapy with the 5-FU prodrug doxifluridine were randomized 1:1 to receive additional therapy with aVQ or no additional therapy. aVQ was injected subcutaneously three times per week from postoperative day 7 to week 24 in increasing doses. EORTC QLQ-C30 and -STO22 Quality of Life questionnaire, differential blood count, liver function tests, various cytokine levels (tumor necrosis factor (TNF)-alpha, interleukin (IL)-2), CD 16(+)/CD56(+) and CD 19(+) lymphocytes were analyzed at baseline and 8, 16 and 24 weeks later.
Global health status (p <0.01), leukocyte- and eosinophil counts (p ≤0.01) increased significantly in the treatment group compared to the control group. Diarrhea was less frequently reported (7% vs. 50%, p=0.014) in the intervention group. There was no significant treatment effect on levels of TNF-alpha, IL-2, CD16(+)/CD56(+) and CD 19(+) lymphocytes and liver function tests measured by ANOVA.
Additional treatment with aVQ is safe and was associated with improved QoL of gastric cancer patients. ClinicalTrials.Gov Registration number NCT01401075.
槲寄生（Viscum album L.）提取物广泛应用于癌症的补充治疗。本研究旨在评估标准化槲寄生提取物（abnobaVISCUM(®) Quercus，aVQ）在胃癌患者中的安全性和疗效。
32 名接受手术治疗的胃癌患者（Ib 期或 II 期）在等待口服氟尿嘧啶前体药物多西氟尿苷化疗时，按 1:1 随机分为接受 aVQ 治疗或不接受额外治疗的两组。aVQ 从术后第 7 天开始每周皮下注射 3 次，剂量逐渐增加，持续到第 24 周。在基线和第 8、16、24 周时，采用 EORTC QLQ-C30 和 -STO22 生活质量问卷、全血细胞计数、肝功能检查、肿瘤坏死因子（TNF）-α、白细胞介素（IL）-2 等多种细胞因子水平、CD16(+)/CD56(+)和 CD19(+)淋巴细胞进行分析。
与对照组相比，治疗组的总体健康状况（p <0.01）、白细胞和嗜酸性粒细胞计数（p ≤0.01）显著增加。治疗组腹泻的发生率明显较低（7% vs. 50%，p=0.014）。方差分析显示，TNF-α、IL-2、CD16(+)/CD56(+)和 CD19(+)淋巴细胞以及肝功能检查的水平没有显著的治疗效果。
aVQ 的额外治疗是安全的，并能改善胃癌患者的生活质量。ClinicalTrials.Gov 注册号 NCT01401075。
